Imexpharm (stock code: IMP) was honored as a representative of Vietnam's pharmaceutical industry among the Top 50 Best Listed Companies in Vietnam during the 11th Annual Business Forum held by Forbes Vietnam in mid-August 2023 in Ho Chi Minh City.
Forbes' Top 50 Best Listed Companies in Vietnam award evaluates businesses based on key financial metrics, sustainable growth, profit sources, corporate governance, and industry outlook. Imexpharm's inclusion in this prestigious list highlights its strong potential, reputation, and internal capabilities. It reflects the company's unwavering commitment to quality as its core strength, ensuring sustainable, balanced development that benefits all stakeholders.
Reflecting on its 2022 achievements, Imexpharm saw net revenue and after-tax profit rise by 30% and 18% year-on-year, respectively. Over the period 2018-2022, the company achieved a compound annual growth rate (CAGR) of 8.5% in net revenue and 12.7% in after-tax profit. Notably, profit growth outpaced revenue, highlighting Imexpharm's exceptional business efficiency. Forbes attributed this impressive performance to effective cost optimization strategies and the expansion of its high-value product portfolio, which includes injectable antibiotics, antiparasitics, and musculoskeletal drugs.
In the first half of 2023, Imexpharm implemented effective strategies focused on market expansion and product portfolio restructuring, driving sustained positive growth. The company achieved cumulative net revenue of VND 919 billion and pre-tax profit of VND 199 billion, marking year-on-year increases of 37% and 59%, respectively. These results represent 57% of Imexpharm's revenue target and 65% of its profit target for 2023, demonstrating strong momentum toward its goals.
Imexpharm’s Board of Directors has recently approved the 2022 dividend plan, under which the company will pay a 15% dividend on its charter capital, consisting of 10% in cash and 5% in shares. As part of this plan, Imexpharm will issue over 3.33 million shares to distribute as dividends to shareholders. The total value of this dividend payment exceeds VND 100 billion, aimed at enhancing shareholder value while bolstering trust and support from both shareholders and investors in Imexpharm and its IMP stock.
With these achievements, along with the recognition as one of the Top 50 Best Listed Companies in Vietnam by Forbes Vietnam, Imexpharm is poised for even greater success in 2023 and beyond. The company remains dedicated to maintaining its position as a highly effective and trustworthy listed company, delivering value to its partners, shareholders, and investors.